• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Alteration of FBXW7 is Associated with Worse Survival in Patients Undergoing Resection of Colorectal Liver Metastases.FBXW7 改变与结直肠癌肝转移切除术后患者的生存预后不良相关。
J Gastrointest Surg. 2021 Jan;25(1):186-194. doi: 10.1007/s11605-020-04866-2. Epub 2020 Nov 17.
2
Mutation Status of , and is Superior to Mutation Status of Alone for Predicting Prognosis after Resection of Colorectal Liver Metastases.对于结直肠癌肝转移切除术后的预后, 突变状态优于 突变状态。
Clin Cancer Res. 2019 Oct 1;25(19):5843-5851. doi: 10.1158/1078-0432.CCR-19-0863. Epub 2019 Jun 20.
3
SMAD4 gene mutation predicts poor prognosis in patients undergoing resection for colorectal liver metastases.SMAD4 基因突变预测结直肠肝转移患者切除术后预后不良。
Eur J Surg Oncol. 2018 May;44(5):684-692. doi: 10.1016/j.ejso.2018.02.247. Epub 2018 Mar 7.
4
Neither Surgical Margin Status nor Somatic Mutation Predicts Local Recurrence After R0-intent Resection for Colorectal Liver Metastases.无论切缘状态还是体突变都不能预测结直肠肝转移 R0 切除术后局部复发。
J Gastrointest Surg. 2022 Apr;26(4):791-801. doi: 10.1007/s11605-021-05173-0. Epub 2021 Nov 1.
5
TP53 Alteration and Its Effect on Pathologic Response Are Associated with Survival after Resection of Colorectal Liver Metastases.TP53 改变及其对病理反应的影响与结直肠肝转移切除术后的生存相关。
J Gastrointest Surg. 2023 Nov;27(11):2597-2600. doi: 10.1007/s11605-023-05759-w. Epub 2023 Aug 8.
6
Improved Survival over Time After Resection of Colorectal Liver Metastases and Clinical Impact of Multigene Alteration Testing in Patients with Metastatic Colorectal Cancer.结直肠癌肝转移切除术后随时间推移生存率的改善以及多基因改变检测对转移性结直肠癌患者的临床影响
J Gastrointest Surg. 2022 Mar;26(3):583-593. doi: 10.1007/s11605-021-05110-1. Epub 2021 Sep 10.
7
Genomic Sequencing and Insight into Clinical Heterogeneity and Prognostic Pathway Genes in Patients with Metastatic Colorectal Cancer.基因组测序与转移性结直肠癌患者临床异质性和预后通路基因的见解。
J Am Coll Surg. 2021 Aug;233(2):272-284.e13. doi: 10.1016/j.jamcollsurg.2021.05.027. Epub 2021 Jun 7.
8
Prospective Study of Perioperative Circulating Tumor DNA Dynamics in Patients Undergoing Hepatectomy for Colorectal Liver Metastases.结直肠癌肝转移患者肝切除围手术期循环肿瘤 DNA 动态的前瞻性研究。
Ann Surg. 2023 May 1;277(5):813-820. doi: 10.1097/SLA.0000000000005461. Epub 2022 Jul 6.
9
RAS/TP53 Co-mutation is Associated With Worse Survival After Concurrent Resection of Colorectal Liver Metastases and Extrahepatic Disease.RAS/TP53 共突变与结直肠肝转移和肝外疾病同时切除后的生存恶化相关。
Ann Surg. 2022 Aug 1;276(2):357-362. doi: 10.1097/SLA.0000000000004672. Epub 2020 Dec 18.
10
Contour prognostic model for predicting survival after resection of colorectal liver metastases: development and multicentre validation study using largest diameter and number of metastases with RAS mutation status.用于预测结直肠肝转移切除术后生存的轮廓预后模型:使用最大直径和 RAS 突变状态的转移瘤数量进行的开发和多中心验证研究。
Br J Surg. 2021 Aug 19;108(8):968-975. doi: 10.1093/bjs/znab086.

引用本文的文献

1
Synthetic tumor extracellular volume as a predictive biomarker for colorectal liver metastasis patients prior to curative hepatectomy.合成肿瘤细胞外容积作为结直肠癌肝转移患者根治性肝切除术前的预测生物标志物。
Eur Radiol. 2025 Mar 24. doi: 10.1007/s00330-025-11503-6.
2
FBXW7 in gastrointestinal cancers: from molecular mechanisms to therapeutic prospects.FBXW7在胃肠道癌症中的研究:从分子机制到治疗前景
Front Pharmacol. 2024 Dec 18;15:1505027. doi: 10.3389/fphar.2024.1505027. eCollection 2024.
3
Co-occurring mutations identify prognostic subgroups of microsatellite stable colorectal cancer.同时发生的突变可确定微卫星稳定结直肠癌的预后亚组。
Mol Cancer. 2024 Nov 25;23(1):264. doi: 10.1186/s12943-024-02173-x.
4
Large-scale genomic analysis of the domestic dog informs biological discovery.对家犬进行大规模基因组分析为生物学发现提供了信息。
Genome Res. 2024 Jul 23;34(6):811-821. doi: 10.1101/gr.278569.123.
5
Targeted variant prevalence of FBXW7 gene mutation in colorectal carcinoma propagation. The first systematic review and meta-analysis.结直肠癌增殖中FBXW7基因突变的靶向变异患病率。首个系统评价与Meta分析。
Heliyon. 2024 May 22;10(11):e31471. doi: 10.1016/j.heliyon.2024.e31471. eCollection 2024 Jun 15.
6
Contemporary Surgical Management of Colorectal Liver Metastases.结直肠癌肝转移的现代外科治疗
Cancers (Basel). 2024 Feb 26;16(5):941. doi: 10.3390/cancers16050941.
7
Locoregional treatment for colorectal liver metastases aiming for precision medicine.以精准医学为目标的结直肠癌肝转移的局部区域治疗。
Ann Gastroenterol Surg. 2023 May 18;7(4):543-552. doi: 10.1002/ags3.12689. eCollection 2023 Jul.
8
Biallelic FBXW7 knockout induces AKAP8-mediated DNA damage in neighbouring wildtype cells.双等位基因FBXW7敲除在邻近野生型细胞中诱导AKAP8介导的DNA损伤。
Cell Death Discov. 2023 Jun 29;9(1):200. doi: 10.1038/s41420-023-01494-y.
9
Integration of Next-Generation Sequencing in the Surgical Management of Colorectal Liver Metastasis.下一代测序在结直肠癌肝转移的外科治疗中的整合。
Ann Surg Oncol. 2023 Oct;30(11):6815-6823. doi: 10.1245/s10434-023-13750-7. Epub 2023 Jun 14.
10
FBXW7 attenuates tumor drug resistance and enhances the efficacy of immunotherapy.FBXW7可减轻肿瘤耐药性并增强免疫治疗效果。
Front Oncol. 2023 Mar 14;13:1147239. doi: 10.3389/fonc.2023.1147239. eCollection 2023.

本文引用的文献

1
Coaltered and Is Associated with Extremes of Survivorship and Distinct Patterns of Metastasis in Patients with Metastatic Colorectal Cancer.在转移性结直肠癌患者中,Coaltered 与生存极限和转移的独特模式相关。
Clin Cancer Res. 2020 Mar 1;26(5):1077-1085. doi: 10.1158/1078-0432.CCR-19-2390. Epub 2019 Nov 12.
2
Extended Molecular Profiling Improves Stratification and Prediction of Survival After Resection of Colorectal Liver Metastases.扩展分子谱分析可改善结直肠癌肝转移切除术后的分层和生存预测。
Ann Surg. 2019 Nov;270(5):799-805. doi: 10.1097/SLA.0000000000003527.
3
Gene mutation and surgical technique: Suggestion or more?基因突变与手术技术:是建议还是更多?
Surg Oncol. 2020 Jun;33:210-215. doi: 10.1016/j.suronc.2019.07.004. Epub 2019 Jul 18.
4
Mutation Status of , and is Superior to Mutation Status of Alone for Predicting Prognosis after Resection of Colorectal Liver Metastases.对于结直肠癌肝转移切除术后的预后, 突变状态优于 突变状态。
Clin Cancer Res. 2019 Oct 1;25(19):5843-5851. doi: 10.1158/1078-0432.CCR-19-0863. Epub 2019 Jun 20.
5
Conditional Recurrence-Free Survival after Resection of Colorectal Liver Metastases: Persistent Deleterious Association with RAS and TP53 Co-Mutation.结直肠肝转移切除后的无复发生存条件:RAS 和 TP53 共突变持续存在有害关联。
J Am Coll Surg. 2019 Sep;229(3):286-294.e1. doi: 10.1016/j.jamcollsurg.2019.04.027. Epub 2019 May 2.
6
Dealing with an insufficient future liver remnant: Portal vein embolization and two-stage hepatectomy.应对未来肝残余量不足:门静脉栓塞与两阶段肝切除术。
J Surg Oncol. 2019 Apr;119(5):594-603. doi: 10.1002/jso.25430. Epub 2019 Mar 1.
7
Is Hepatectomy Justified for BRAF Mutant Colorectal Liver Metastases?: A Multi-institutional Analysis of 1497 Patients.BRAF 突变结直肠癌肝转移行肝切除术是否合理?:1497 例患者的多机构分析。
Ann Surg. 2020 Jan;271(1):147-154. doi: 10.1097/SLA.0000000000002968.
8
Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer.BRAF 突变与手术治疗转移性结直肠癌肝转移患者生存和复发的关系。
JAMA Surg. 2018 Jul 18;153(7):e180996. doi: 10.1001/jamasurg.2018.0996.
9
Oncogenic Signaling Pathways in The Cancer Genome Atlas.癌症基因组图谱中的致癌信号通路。
Cell. 2018 Apr 5;173(2):321-337.e10. doi: 10.1016/j.cell.2018.03.035.
10
SMAD4 gene mutation predicts poor prognosis in patients undergoing resection for colorectal liver metastases.SMAD4 基因突变预测结直肠肝转移患者切除术后预后不良。
Eur J Surg Oncol. 2018 May;44(5):684-692. doi: 10.1016/j.ejso.2018.02.247. Epub 2018 Mar 7.

FBXW7 改变与结直肠癌肝转移切除术后患者的生存预后不良相关。

Alteration of FBXW7 is Associated with Worse Survival in Patients Undergoing Resection of Colorectal Liver Metastases.

机构信息

Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1484, Houston, TX, 77030, USA.

Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

出版信息

J Gastrointest Surg. 2021 Jan;25(1):186-194. doi: 10.1007/s11605-020-04866-2. Epub 2020 Nov 17.

DOI:10.1007/s11605-020-04866-2
PMID:33205306
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10095595/
Abstract

BACKGROUND

For patients undergoing resection of colorectal liver metastases (CLMs), the prognostic role of somatic gene alterations is increasingly recognized. F-box/WD repeat-containing protein 7 (FBXW7) is a tumor suppressor gene found in approximately 10% of patients with colorectal cancer. The aim of this study is to assess the association of FBXW7 with overall survival after CLM resection.

METHODS

Patients who underwent initial CLM resection during 2001-2016 and had genetic sequencing data were studied. Risk factors for overall survival (OS) were evaluated with Cox proportional hazards models using backward elimination.

RESULTS

Of 2045 patients who underwent CLM resection during the study period, 476 were included. The majority (90.5%) underwent prehepatectomy chemotherapy. A total of 27 patients (5.7%) had FBXW7 alteration, along with 240 (50.4%) RAS, 337 (70.8%) TP53, 51 (10.7%) SMAD4, and 27 (5.7%) BRAF. Cox proportional hazards model analyses including 5 somatic gene alteration status and 12 clinicopathologic factors revealed FBXW7(hazard ratio [HR] 1.99, P = 0.015), BRAF (HR 2.47, P = 0.023), RAS (HR 2.42, P < 0.001), TP53 (HR 2.00, P < 0.001), and SMAD4 alterations (HR 1.90, P = 0.004) as significantly associated with OS, together with three clinicopathologic factors, prehepatectomy chemotherapy > 6 cycles (HR 1.51, P = 0.021), number of CLM (HR 1.05, P = 0.007), and largest liver metastasis diameter (HR 1.07, P = 0.023). The covariate-adjusted 5-year OS was significantly lower in patients with FBXW7 alteration than in patients with FBXW7 wild-type (40.4% vs.59.4%, P = 0.015).

CONCLUSIONS

FBXW7 alterations are associated with worse survival after CLM resection. The information on multiple somatic gene alterations is imperative for risk stratification and patient selection for CLM resection.

摘要

背景

对于接受结直肠肝转移(CLM)切除术的患者,体细胞基因突变的预后作用越来越受到重视。F-box/WD 重复蛋白 7(FBXW7)是一种肿瘤抑制基因,约 10%的结直肠癌患者存在该基因改变。本研究旨在评估 FBXW7 与 CLM 切除术后总生存期的关系。

方法

研究纳入了 2001 年至 2016 年期间接受初始 CLM 切除术且具有基因测序数据的患者。使用向后消除的 Cox 比例风险模型评估总生存期(OS)的危险因素。

结果

在研究期间,2045 例患者接受了 CLM 切除术,其中 476 例患者被纳入。大多数患者(90.5%)接受了肝切除术前化疗。共有 27 例(5.7%)患者存在 FBXW7 改变,同时 240 例(50.4%)患者存在 RAS 改变,337 例(70.8%)患者存在 TP53 改变,51 例(10.7%)患者存在 SMAD4 改变,27 例(5.7%)患者存在 BRAF 改变。包括 5 种体细胞基因突变状态和 12 种临床病理因素的 Cox 比例风险模型分析显示,FBXW7(风险比 [HR] 1.99,P = 0.015)、BRAF(HR 2.47,P = 0.023)、RAS(HR 2.42,P < 0.001)、TP53(HR 2.00,P < 0.001)和 SMAD4 改变(HR 1.90,P = 0.004)与 OS 显著相关,同时还有 3 种临床病理因素,即肝切除术前化疗>6 个周期(HR 1.51,P = 0.021)、CLM 数量(HR 1.05,P = 0.007)和最大肝转移直径(HR 1.07,P = 0.023)。FBXW7 改变患者的 5 年 OS 明显低于 FBXW7 野生型患者(40.4% vs. 59.4%,P = 0.015)。

结论

FBXW7 改变与 CLM 切除术后生存不良相关。多种体细胞基因突变的信息对 CLM 切除术的风险分层和患者选择至关重要。